Ligand Pharmaceuticals (LGND) stock surged 5.07% on Friday, outperforming the broader market during the intraday trading session. The biopharmaceutical company's impressive rally followed the release of its Q4 2024 earnings results and positive analyst sentiment.
During the Q4 earnings call, Ligand Pharmaceuticals reported a 28% increase in royalty revenue and a 40% increase in core adjusted EPS for 2024. The company successfully launched two new commercial products, Veronaarma Auteuve and Merck's capaci, both exceeding sales expectations. Additionally, Ligand has a diversified portfolio of commercial stage royalty assets and a robust pipeline of development stage opportunities.
Adding to the positive sentiment, RBC Capital Markets raised its price target on Ligand Pharmaceuticals to $155 from $143, maintaining an Outperform rating. The analyst's bullish outlook reflects the company's strong financial position, restructured business model focused on profitable growth, and promising prospects for future growth drivers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。